Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07107841

Blinded, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for the Treatment of Androgenic Alopecia (Single Site)

Led by Acorn Biolabs Inc. · Updated on 2026-02-12

60

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating an autologous hair follicle-derived secretome as a treatment for androgenic alopecia, a common cause of hair loss affecting men and women. This trial aims to study the safety and effectiveness of injecting this secretome into the scalp compared to a saline placebo. The study will include 60 patients who have been on a stable regimen of minoxidil and 5-alpha reductase inhibitors for at least six months. Participants will receive injections of the secretome diluted with saline or placebo at baseline and on days 30, 90, 180, 270, and 365. The injections will be administered in a grid-like pattern across affected areas of the scalp, with about 20 injections per quadrant. Each vial of secretome is diluted in 2ml saline, and each quadrant receives one vial. The study is double-blind and placebo-controlled. During the trial, hair growth will be measured by density and thickness at various time points, and patient-reported outcomes will be collected. Safety will be monitored, with assessments including Target Area Hair Counts and patient satisfaction. Participants must attend all study visits and agree to maintain their hairstyle and tolerate injections. The total study duration is one year, with multiple follow-up assessments.

CONDITIONS

Brief Title

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 65 years
  • Diagnosed with androgenic alopecia
  • On a stable course of minoxidil (oral or topical) and/or 5-alpha reductase inhibitors for at least 12 months prior to baseline
  • Female subjects must not have used hair growth medications or topicals for at least 6 months prior to baseline
  • Willing to maintain current hair style during the study
  • Able and willing to tolerate multiple scalp injections
  • Able to attend all study-related clinical visits
  • Willing to have small UV or red tattoo dots applied to the scalp to mark treatment areas
  • Competent and willing to provide written informed consent
Not Eligible

You will not qualify if you...

  • Diagnosis of alopecia areata or other non-androgenic alopecia forms
  • Active scalp skin diseases such as psoriasis or severe seborrheic dermatitis
  • Scalp infection or cuts/abrasions on the scalp
  • Severe active systemic infection
  • History of surgical hair restoration within the last 12 months
  • Current or recent malignancy within 5 years (except basal or squamous cell skin cancers)
  • History of systemic chemotherapy or radiation
  • History of thyroid dysfunction or autoimmune disorders (e.g., Graves disease, Hashimoto thyroiditis, systemic lupus erythematosus)
  • Continuous daily use of NSAIDs or Vitamin E unless discontinued 7 days before first treatment
  • Use of medications causing drug-induced hair loss within last 3 months
  • Known allergy or sensitivity to tattoo ink
  • Current anticoagulant therapy
  • Significant tendency to develop keloids or hypertrophic scarring
  • Unable to communicate with study staff
  • Any health condition deemed by investigator to preclude participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 1 year

Participants receive injections of either autologous hair follicle-derived secretome or placebo saline to affected scalp areas to stimulate hair regrowth.

6 injection visits on Day 0, Day 30, Day 90, Day 180, Day 270, and Day 365

Trial Site Locations

Total: 1 location

1

Ziering Medical

West Hollywood, California, United States, 90069

Actively Recruiting

Loading map...

Research Team

L

Lisa M Campbell, PhD

H

Heather Dwyer

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Pivotal Clinical Study to Evaluate the Efficacy and Safety...

Androgenic Alopecia

Actively Recruiting

2 locations

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Tria...

Areata Alopecia

Actively Recruiting

127 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here